Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
We send one confirmation email first. Only emails about INVA, unsubscribe in one click. Privacy
Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.
| Drug | Indication | Most advanced trial | Status |
|---|---|---|---|
| Trimethoprim-Sulfamethoxazole | Mycobacterium Abscessus Pulmonary Disease | Phase 2 · NCT07485010 | Not yet recruiting |
| Sulbactam | Mycobacterium Abscessus Pulmonary Disease | Phase 2 · NCT07485010 | Not yet recruiting |
| Moxifloxacin | Mycobacterium Abscessus Pulmonary Disease | Phase 2 · NCT07485010 | Not yet recruiting |
| IV Eravacycline 1.5mg/kg | Complicated Intra-abdominal Infections (cIAI) | Phase 2 · NCT06794541 | Recruiting |
| Imipenem | Mycobacterium Abscessus Pulmonary Disease | Phase 2 · NCT07485010 | Not yet recruiting |
| Ethambutol | Mycobacterium Abscessus Pulmonary Disease | Phase 2 · NCT07485010 | Not yet recruiting |
| Ceftriaxone | Mycobacterium Abscessus Pulmonary Disease | Phase 2 · NCT07485010 | Not yet recruiting |
| Bedaquiline | Mycobacterium Abscessus Pulmonary Disease | Phase 2 · NCT07485010 | Not yet recruiting |
| Azithromcyin | Mycobacterium Abscessus Pulmonary Disease | Phase 2 · NCT07485010 | Not yet recruiting |
Also used in these trials (approved or third-party drugs, not INVA's own candidates): Angiotensin Ii, Ceftobiprole Medocaril Sodium, Amikacin, Tigecycline, Rifabutin, Linezolid, Doxycycline, Clofazimine, Clarithromycin, Cefoxitin Sodium, Amoxicillin.
Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it
INVA holds $1.1B in cash and short-term investments (as of Sep 30, 2026) and its operations are currently cash-flow neutral or positive.
Dilution pressure: 0 · Low
Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when INVA files for a raise →
| Holder | Type | Shares | % of shares | As of |
|---|---|---|---|---|
| Innoviva, Inc. | 5%+ holder (13D) | 55,467,459 | 78.03% | 2026-05-12 |
| BlackRock, Inc. | Institution (13G, 5%+) | 11,138,961 | 15.67% | 2026-09-30 |
| Alexander J Denner 10% owner |
Insider | 5,658,705 | 7.96% | 2025-03-04 |
| Dimensional Fund Advisors LP | Institution (13G, 5%+) | 4,360,401 | 6.13% | 2025-12-31 |
| Vanguard Portfolio Management | Institution (13G, 5%+) | 4,288,063 | 6.03% | 2026-03-31 |
| Renaissance Technologies LLC | Institution (13G, 5%+) | 4,210,172 | 5.92% | 2025-12-31 |
| Vanguard Capital Management | Institution (13G, 5%+) | 3,704,185 | 5.21% | 2026-06-30 |
| Pavel Raifeld Chief Executive Officer, Director · +1.38M options |
Insider | 284,799 | 0.40% | 2026-08-20 |
| Jules Haimovitz Director · +20,000 options |
Insider | 152,692 | 0.21% | 2026-05-04 |
| Mark DiPaolo Director · +20,000 options |
Insider | 140,492 | 0.20% | 2026-05-04 |
| Sarah J. Schlesinger Director · +20,000 options |
Insider | 140,492 | 0.20% | 2026-05-04 |
| Stephen Basso Chief Financial Officer · +370,480 options |
Insider | 88,013 | 0.12% | 2026-08-20 |
Share count 71,081,477 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest. Sources have different dates, so the split is approximate. Source: SEC EDGAR.
| Date | Drug | Type | Run-up 30d | Decision 1d | After 5d |
|---|---|---|---|---|---|
| 2025-11-05 | NUZOLVENCE® (zoliflodacin) | NDA | +4.2% | +0.4% | +20.7% |
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for INVA and every other ticker you follow. Card required, cancel anytime.
Start 7-day free trial →